[1]Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021,149:1-61. [2]Zhang J, Li H, Dong J, et al. Omics-based identification of shared and gender disparity routes in Hras12V-induced hepatocarcinogenesis: an important role for Dlk1-Dio3 genomic imprinting region[J]. Front Genet, 2021, 12: 620594. doi: 10.3389/fgene.2021.620594. [3]Wang AG, Moon HB, Lee MR, et al. Gender-dependent hepatic alterations in H-ras 12V transgenic mice[J]. Hepatol, 2005, 43: 836-844. [4]Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation[J]. J Transplant, 2009: 701464. doi: 10.1155/2009/701464. [5]Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice[J]. Nature, 2009, 460: 392-395. [6]Malagelada C, Jin ZH, Jackson-Lewis V, et al. Rapamy-cin protects against neuron death in in vitro and in vivo models of Parkinson's disease[J]. J Neurosci, 2010, 30: 1166-1175. [7]Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019, 12:71. doi: 10.1186/s13045-019-0754-1. [8]Sun L, Yan Y, Lv H, et al. Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth[J]. Cell Chem Biol, 2022, 29: 373-385. [9]Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health[J]. Oncotarget, 2011, 2:135-164. [10]Albert L, Karsy M, Murali R, et al. Inhibition of mTOR activates the MAPK pathway in glioblastoma[J]. Cancer Genom Proteom, 2009, 6: 255-261. [11]马家玲, 高艳平. miR-183靶向Bnip3l对缺氧/复氧的小鼠海马神经元细胞线粒体自噬的影响[J]. 基础医学与临床, 2021, 41: 698-703. [12]Zhu W, Liu X, He J, et al. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study[J]. BMC Cancer, 2011, 11: 393. doi:10.1186/1471-2407-11-393. [13]Stephan C, Jung M, Rabenhorst S, et al. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue[J]. Clin Chem Lab Med, 2015, 53: 1109-1118. [14]Li J, Fu H, Xu C, et al. MiR-183 inhibits TGF-β1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells[J]. BMC Cancer, 2010, 10: 354-363. [15]Niu Y, Liu F, Wang X, et al. miR-183-5p promotes HCC migration/invasion via increasing aerobic glycolysis [J]. Onco Targets Ther, 2021, 14: 3649-3658. |